| Complete remission of philadelphia chromosome-positive acute myeloid leukemia with imatinib mesylate |
|
Saet Byul Jang, Sung Hwa Bae, Hye Ryun Jung, So Yeon Yoon, Eon Ju Jun, Gun Woo Kang, Hun Mo Ryoo |
|
|
| 필라델피아 양성 급성골수성 백혈병에서 imatinib mesylate 투여로 완전관해 유도된 1예 |
|
장샛별, 배성화, 정혜련, 윤소연, 전언주, 강건우, 류헌모 |
|
|
|
|
|
|
| Abstract |
|
Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML) is a rare disease characterized by a poor prognosis with
resistance to standard chemotherapy. We report a patient with Ph+AML with a minor BCR-ABL-positive mRNA transcript who
achieved a hematologic, cytogenetic, and major molecular complete response after cytarabine-based chemotherapy followed by
imatinib. After more than 6 months of continuous imatinib therapy, the patient is in continuous complete remission. Our results
show that imatinib mesylate is effective in treating Ph+AML. (Korean J Med 78:132-137, 2010) |
| Key Words:
Leukemia; Myeloid; Acute; Philadelphia chromosome; Imatinib mesylate |
|
PDF Links
Full text via DOI
Download Citation
